BioSpace News Archive

Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today that Robert Scannevin, Ph.D., will join the company as Chief Scientific Officer

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine” to fight SARS-CoV-2, today provided guidance on the terms of its agreement with Beijing Youfeng Biological Technology,

Baylis Medical is proud to announce that it is a Gold Standard Winner of the Canada’s Best Managed Companies award.

Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, today announced it will provide COVID-19 saliva PCR testing for select independent pharmacies through Benasource, a leading group purchasing organization and provider of telemedicine solutions and digital pharmacy savings.

Altasciences, a forward-thinking CRO/CDMO supporting all crucial steps in early-stage drug development, from lead candidate selection to clinical proof of concept, announced today that they have completed the acquisition of Calvert Laboratories, a preclinical CRO located on the U.S.A.’s East Coast.

New agreement sees Isohelix GeneFix™ Saliva DNA and RNA Collection Devices integrated into AutoGen FlexSTAR DNA extraction workflows

Accelerate Diagnostics, Inc. announced that management will host a conference call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time to review 2021 first quarter financial results.

Maravai LifeSciences, Inc., a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of May.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, reported financial results for the first quarter ended March 31, 2021.

Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, reported that on May 3, 2021, the Company granted non-qualified stock options to purchase an aggregate of 51,200 shares of the Company’s common stock to six new employees.